Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lorcaserin, a selective serotonin 2C receptor agonist that modulates appetite, has proven efficacy for weight management in overweight or obese patients. The cardiovascular safety and efficacy of lorcaserin are undefined. METHODS: We randomly assigned 12,000 overweight or obese patients with atherosclerotic cardiovascular disease or multiple cardiovascular risk factors to receive either lorcaserin (10 mg twice daily) or placebo. The primary safety outcome of major cardiovascular events (a composite of cardiovascular death, myocardial infarction, or stroke) was assessed at an interim analysis to exclude a noninferiority boundary of 1.4. If noninferiority was met, the primary cardiovascular efficacy outcome (a composite of major cardiovascular events, heart failure, hospitalization for unstable angina, or coronary revascularization [extended major cardiovascular events]) was assessed for superiority at the end of the trial. RESULTS: At 1 year, weight loss of at least 5% had occurred in 1986 of 5135 patients (38.7%) in the lorcaserin group and in 883 of 5083 (17.4%) in the placebo group (odds ratio, 3.01; 95% confidence interval [CI], 2.74 to 3.30; P<0.001). Patients in the lorcaserin group had slightly better values with respect to cardiac risk factors (including blood pressure, heart rate, glycemic control, and lipids) than those in the placebo group. During a median follow-up of 3.3 years, the rate of the primary safety outcome was 2.0% per year in the lorcaserin group and 2.1% per year in the placebo group (hazard ratio, 0.99; 95% CI, 0.85 to 1.14; P<0.001 for noninferiority); the rate of extended major cardiovascular events was 4.1% per year and 4.2% per year, respectively (hazard ratio, 0.97; 95% CI, 0.87 to 1.07; P=0.55). Adverse events of special interest were uncommon, and the rates were generally similar in the two groups, except for a higher number of patients with serious hypoglycemia in the lorcaserin group (13 vs. 4, P=0.04). CONCLUSIONS: In a high-risk population of overweight or obese patients, lorcaserin facilitated sustained weight loss without a higher rate of major cardiovascular events than that with placebo. (Funded by Eisai; CAMELLIA-TIMI 61 ClinicalTrials.gov number, NCT02019264 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“the concept of treating obesity to reduce the risk of cardiovascular complications has been hampered by the lack of evidence from trials indicating that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes. 11-15”
From Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (2023) · cites this paper as [12]
In the citing paper
“Prospective studies that evaluated the effect of nonsurgical weight loss interventions on CV event reduction have been disappointing [4, 5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [8]
In the citing paper
“Specifically, across the obesity CVOTs, SELECT is the only study to our knowledge that only enrolled participants with established CVD, whereas in the other obesity CVOTs, 24.9% to 50.5% of participants had no prior events [5, 6, 7, 8].”
From Semaglutide for cardiovascular event reduction in people with overweight or obesity: SELECT study baseline characteristics (2023) · cites this paper as [8]
In the citing paper
“lorcaserin, which had a neutral effect on MACEs in the CAMELLIA-TIMI 61 study”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [173]
Citations
Cites
Health effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects
Sjöström, L., Narbro, K., Sjöström, C. D., Karason, K., Larsson, B., Wedel, H., Lystig, T., Sullivan, M., Bouchard, C., Carlsson, B., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066254 · Cited by 4,668
2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.004 · Cited by 4,058
Flegal, K. M., Kit, B. K., Orpana, H., & Graubard, B. I. (2013) · JAMA · doi:10.1001/jama.2012.113905 · Cited by 3,998
Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes
The Look AHEAD Research Group (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1212914 · Cited by 2,908
Jensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Hales, C. M., Fryar, C. D., Carroll, M. D., Freedman, D. S., & Ogden, C. L. (2018) · JAMA · doi:10.1001/jama.2018.3060 · Cited by 1,761
Bariatric Surgery and Long-term Cardiovascular Events
Sjöström, L., Peltonen, M., Jacobson, P., Sjöström, C. D., Karason, K., Wedel, H., Ahlin, S., Anveden, Å., Bengtsson, C., Bergmark, G., et al. (2012) · JAMA · doi:10.1001/jama.2011.1914 · Cited by 1,656
Valvular heart disease associated with fenfluramine-phentermine
Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., & Schaff, H. V. (1997) · New England Journal of Medicine · doi:10.1056/nejm199708283370901 · Cited by 1,632
Cited by
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Obesity and cardiovascular disease: revisiting an old relationship
Koliaki, C., Liatis, S., & Kokkinos, A. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.011 · Cited by 719
Cardiovascular Safety of Testosterone-Replacement Therapy
Lincoff, A. M., Bhasin, S., Flevaris, P., Mitchell, L. M., Basaria, S., Boden, W. E., Cunningham, G. R., Granger, C. B., Khera, M., Thompson, I. M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2215025 · Cited by 475
Signaling pathways in obesity: mechanisms and therapeutic interventions
Wen, X., Zhang, B., Wu, B., Xiao, H., Li, Z., Li, R., Xu, X., & Li, T. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01149-x · Cited by 410
Emerging Roles for Serotonin in Regulating Metabolism: New Implications for an Ancient Molecule
Yabut, J. M., Crane, J. D., Green, A. E., Keating, D. J., Khan, W. I., & Steinberg, G. R. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00283 · Cited by 411
Cardiovascular risk and obesity
Cercato, C., & Fonseca, F. A. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0468-0 · Cited by 395
“The overall results of this trial suggested cardiovascular safety in a large high-risk population of subjects with overweight or obesity [70] (Table 1).”
BackgroundMackenzie, I. S., Ford, I., Nuki, G., Hallas, J., Hawkey, C. J., Webster, J., Ralston, S. H., Walters, M., Robertson, M., De Caterina, R., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32234-0 · Cited by 352
Diabesity: the combined burden of obesity and diabetes on heart disease and the role of imaging
Ng, A. C. T., Delgado, V., Borlaug, B. A., & Bax, J. J. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-020-00465-5 · Cited by 331
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
Self-citationCurrent treatments for obesity
Ruban, A., Stoenchev, K., Ashrafian, H., & Teare, J. (2019) · Clinical Medicine · doi:10.7861/clinmedicine.19-3-205 · Cited by 266
Progress in adjuvant systemic therapy for breast cancer
Pondé, N. F., Zardavas, D., & Piccart, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0089-9 · Cited by 281
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Vest, A. R., Chan, M., Deswal, A., Givertz, M. M., Lekavich, C., Lennie, T., Litwin, S. E., Parsly, L., Rodgers, J. E., Rich, M. W., et al. (2019) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2019.03.007 · Cited by 230
“The cardiovascular safety study of naltrexone-bupropion did not report HF outcomes, and the lorcaserin safety study showed a neutral outcome for HF at 40 months of follow-up.(56)”
BackgroundRangel-Huerta, O. D., Pastor-Villaescusa, B., & Gil, A. (2019) · Metabolomics · doi:10.1007/s11306-019-1553-y · Cited by 221
Serotonin, food intake, and obesity
van Galen, K. A., ter Horst, K. W., & Serlie, M. J. (2021) · Obesity Reviews · doi:10.1111/obr.13210 · Cited by 197
“More recently, the 5-HT2C receptor agonist lorcaserin was shown to be effective in reducing food intake, body weight, and cardiometabolic complications in individuals with obesity.(165) It was used in clinical practice across the United States from 2012 to 2020, at which time the FDA requested it be withdrawn from the…”
BackgroundAnti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Tak, Y. J., & Lee, S. Y. (2021) · The World Journal of Men's Health · doi:10.5534/wjmh.200010 · Cited by 184
RSSDI-ESI clinical practice recommendations for the management of type 2 diabetes mellitus 2020
Madhu, S., Chawla, R., Makkar, B., Ghosh, S., Saboo, B., & Kalra, S. (2020) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_225_20 · Cited by 167
“Lorcaserin facilitated the sustained weight loss without a higher rate of major cardiovascular events.[643] However, the USFDA has issued a request to withdraw lorcaserin from the markets due to increased occurrence of cancer, based on a recent long-term safety study.”
BackgroundOussaada, S. M., van Galen, K. A., Cooiman, M. I., Kleinendorst, L., Hazebroek, E. J., van Haelst, M. M., ter Horst, K. W., & Serlie, M. J. (2019) · Metabolism · doi:10.1016/j.metabol.2018.12.012 · Cited by 180
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s008 · Cited by 148
Cancer Risk Associated with Lorcaserin — The FDA’s Review of the CAMELLIA-TIMI 61 Trial
Sharretts, J., Galescu, O., Gomatam, S., Andraca-Carrera, E., Hampp, C., & Yanoff, L. (2020) · New England Journal of Medicine · doi:10.1056/nejmp2003873 · Cited by 147
Diabetic cardiomyopathy: prevalence, determinants and potential treatments
Gulsin, G. S., Athithan, L., & McCann, G. P. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819834869 · Cited by 158
Clinical Considerations Regarding the Use of Obesity Pharmacotherapy in Adolescents with Obesity
Srivastava, G., Fox, C. K., Kelly, A. S., Jastreboff, A. M., Browne, A. F., Browne, N. T., Pratt, J. S. A., Bolling, C., Michalsky, M. P., Cook, S., et al. (2019) · Obesity · doi:10.1002/oby.22385 · Cited by 130
“No adverse cardiovascular safety signals have thus far emerged with lorcaserin from the large cardiovascular safety trial (108).”
BackgroundSingh, A. K., & Singh, R. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1698291 · Cited by 130
“Although no change in HR was observed with lorcaserin, a reduction of −1 to −2 beat per minute was observed in the BLOOM-DM and the CAMELLIA-TIMI 61 [28,29].”
MethodMichos, E. D., Reddy, T. K., Gulati, M., Brewer, L. C., Bond, R. M., Velarde, G. P., Bailey, A. L., Echols, M. R., Nasser, S. A., Bays, H. E., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100250 · Cited by 126
Pandey, A., Patel, K. V., Bahnson, J. L., Gaussoin, S. A., Martin, C. K., Balasubramanyam, A., Johnson, K. C., McGuire, D. K., Bertoni, A. G., Kitzman, D., et al. (2020) · Circulation · doi:10.1161/circulationaha.119.044865 · Cited by 127
Self-citationLingvay, I., Brown‐Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt‐Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · Obesity · doi:10.1002/oby.23621 · Cited by 113
Cardiometabolic-Based Chronic Disease, Addressing Knowledge and Clinical Practice Gaps
Mechanick, J. I., Farkouh, M. E., Newman, J. D., & Garvey, W. T. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.046 · Cited by 113
Describing the Weight‐Reduced State: Physiology, Behavior, and Interventions
Aronne, L. J., Hall, K. D., M. Jakicic, J., Leibel, R. L., Lowe, M. R., Rosenbaum, M., & Klein, S. (2021) · Obesity · doi:10.1002/oby.23086 · Cited by 113
“The CAMELLIA- TIMI 61 trial was the first longterm cardiovascular outcome trial involving a medication used specifically for obesity, lorcaserin, a selective serotonin 2c receptor agonist that suppresses appetite (127).”
BackgroundResultMichos, E. D., Lopez‐Jimenez, F., & Gulati, M. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.029282 · Cited by 90
Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32328-6 · Cited by 94
Self-citationManagement of Obesity in Cardiovascular Practice
Després, J.-P., Carpentier, A. C., Tchernof, A., Neeland, I. J., & Poirier, P. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.05.035 · Cited by 87
Childhood obesity: A review of current and future management options
Apperley, L. J., Blackburn, J., Erlandson‐Parry, K., Gait, L., Laing, P., & Senniappan, S. (2021) · Clinical Endocrinology · doi:10.1111/cen.14625 · Cited by 99
“(including pancreatic, colorectal and lung) and therefore FDA approval was removed in 2020.(145,146) At present, there is no published”
BackgroundThe Role of the Gut Microbiota in the Gut–Brain Axis in Obesity: Mechanisms and Future Implications
van Son, J., Koekkoek, L. L., la Fleur, S. E., Serlie, M. J. M., & Nieuwdorp, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22062993 · Cited by 91
“The serotonin 2C receptor agonist, lorcaserin, was found to significantly improve weight loss in individuals with obesity [161], but was recently withdrawn from the market after reports of increased cancer risk [162].”
BackgroundWeight Loss Medications in the Treatment of Obesity and Hypertension
Cohen, J. B., & Gadde, K. M. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0915-1 · Cited by 76
Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential
Higgins, G. A., Fletcher, P. J., & Shanahan, W. R. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107417 · Cited by 82
Cardiovascular outcome trials in obesity: A review
Wilding, J. P. H., & Jacob, S. (2021) · Obesity Reviews · doi:10.1111/obr.13112 · Cited by 75
“Of note, in the obesity CVOTs conducted to date, more than 85% of the trial populations are White.(53,55) 6 of 11 WILDING AND JACOB”
BackgroundInfluentialChoi, W. G., Choi, W., Oh, T. J., Cha, H.-N., Hwang, I., Lee, Y. K., Lee, S. Y., Shin, H., Lim, A., Ryu, D., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145331 · Cited by 76
Tsai, A. G., & Bessesen, D. H. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201903050 · Cited by 83
Long-term effects of weight-reducing drugs in people with hypertension
Siebenhofer, A., Winterholer, S., Jeitler, K., Horvath, K., Berghold, A., Krenn, C., & Semlitsch, T. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007654.pub5 · Cited by 70
Patel, K. V., Bahnson, J. L., Gaussoin, S. A., Johnson, K. C., Pi-Sunyer, X., White, U., Olson, K. L., Bertoni, A. G., Kitzman, D. W., Berry, J. D., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.050941 · Cited by 69
Wen, J.-J., Li, M., Gao, H., Hu, J., Nie, Q., Chen, H., Zhang, Y.-L., Xie, M., & Nie, S. (2021) · Food & Function · doi:10.1039/d0fo02600j · Cited by 70
An evaluation of liraglutide including its efficacy and safety for the treatment of obesity
Lin, C.-H., Shao, L., Zhang, Y.-M., Tu, Y.-J., Zhang, Y., Tomlinson, B., Chan, P., & Liu, Z. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1695779 · Cited by 65
“loss without a higher rate of major cardiovascular events than that with placebo in a high-risk population of overweight or obese patients [19].”
BackgroundCardiovascular Safety and Sclerostin Inhibition
Langdahl, B. L., Hofbauer, L. C., & Forfar, J. C. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab193 · Cited by 67
Treatment of Obesity in Mitigating Metabolic Risk
Heffron, S. P., Parham, J. S., Pendse, J., & Alemán, J. O. (2020) · Circulation Research · doi:10.1161/circresaha.119.315897 · Cited by 59
Obesity-Associated Organ Damage and Sympathetic Nervous Activity: A Target for Treatment?
Lambert, É., Esler, M., Schlaich, M. P., Dixon, J. B., Eikelis, N., & Lambert, G. W. (2019) · Hypertension · doi:10.1161/hypertensionaha.118.11676 · Cited by 65
Bhasin, S., Lincoff, A. M., Nissen, S. E., Wannemuehler, K. A., McDonnell, M. E., Peters, A. L., Khan, N., Snabes, M. C., Li, X., Li, G., et al. (2024) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2023.7862 · Cited by 65
Pharmacotherapy of obesity: An update
Cignarella, A., Busetto, L., & Vettor, R. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105649 · Cited by 65
Malden, D. E., Lacey, B., Emberson, J., Karpe, F., Allen, N. E., Bennett, D., & Lewington, S. (2019) · Obesity · doi:10.1002/oby.22509 · Cited by 61
Medications for the treatment of obesity in adolescents
Woodard, K., Louque, L., & Hsia, D. S. (2020) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820918789 · Cited by 53
The Effect of Semaglutide on Mortality and COVID-19–Related Deaths
Scirica, B. M., Lincoff, A. M., Lingvay, I., Bogdanski, P., Buscemi, S., Colhoun, H., Craciun, A.-E., Ezhov, M., Hardt-Lindberg, S., Kleist Jeppesen, O., et al. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.08.007 · Cited by 51
Self-citationLam, C. S. P., Rodríguez, Á., Aminian, A., Ferrannini, E., Heerspink, H. J. L., Jastreboff, A. M., Laffin, L. J., Pandey, A., Ray, K. K., Ridker, P. M., et al. (2025) · Obesity · doi:10.1002/oby.24332 · Cited by 59
“Unfortunately, most clinical trials examining lifestyle and conventional pharmacological treatments for weight management in people with obesity failed to demonstrate a reduction in morbidity and mortality, with some associated with serious adverse events [14 – 17].”
Role of serotonin in body weight, insulin secretion and glycaemic control
Georgescu, T. R., Lyons, D. J., & Heisler, L. K. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.12960 · Cited by 51
Nonogaki, K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031600 · Cited by 53
Tuccinardi, D., Farr, O. M., Upadhyay, J., Oussaada, S. M., Mathew, H., Paschou, S. A., Perakakis, N., Koniaris, A., Kelesidis, T., & Mantzoros, C. S. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13655 · Cited by 47
“5-hydroxytryptamine 2c (5-HT2c) receptor agonist, effective for longterm weight management,(4,5) is also safe, showing no increase in cardiovascular events, in addition to contributing to the prevention and remission of type 2 diabetes.(6,7) Although large clinical trials have shown an early reduction in weight-indepe…”
BackgroundThe risk of chronic psychedelic and MDMA microdosing for valvular heart disease
Tagen, M., Mantuani, D., van Heerden, L., Holstein, A., Klumpers, L. E., & Knowles, R. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231190865 · Cited by 48
“A post-marketing safety study required by the FDA compared 12,000 patients randomized to lorcaserin or placebo treatment for 1 year and confirmed that there was no greater risk of VHD in those treated with lorcaserin (Bohula et al., 2018).”
RSSDI-ESI Clinical Practice Recommendations for the Management of Type 2 Diabetes Mellitus 2020
Chawla, R., Madhu, S. V., Makkar, B. M., Ghosh, S. K., Saboo, B., Kalra, S., & On behalf of RSSDI-ESI Consensus Group (2020) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-020-00819-2 · Cited by 61
Is lorcaserin really associated with increased risk of cancer? A systematic review and meta‐analysis
Mesquita, L. D. A., Piccoli, G. F., da Natividade, G. R., Spiazzi, B. F., Colpani, V., & Gerchman, F. (2020) · Obesity Reviews · doi:10.1111/obr.13170 · Cited by 44
“Albeit lorcaserin was safe from a cardiovascular perspective, it did not confer any protection against cardiovascular events.(7) In addition, as an antiobesity drug, lorcaserin promoted only discrete additional weight loss compared with placebo: 3.”
BackgroundResultObesity, diabetes, and cancer: epidemiology, pathophysiology, and potential interventions
Mesquita, L. D. A., Wayerbacher, L. F., Schwartsmann, G., & Gerchman, F. (2023) · Archives of Endocrinology and Metabolism · doi:10.20945/2359-3997000000647 · Cited by 52
“…61 trial reported no imbalance in neoplasms with lorcaserin compared with placebo, a FDA review with follow-up data from this trial found a disproportional (although non-significant) increase in cancer cases in the lorcaserin group, motivating the market withdrawal of the drug (120,121).”
BackgroundAlsaqaaby, M. S., Cooney, S., le Roux, C. W., & Pournaras, D. J. (2024) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(24)00098-6 · Cited by 39
Jansy Isabella Rani, A., Uddandrao, V. V. S., Govindasami, S., Saravanan, G., Chandrasekaran, P., Sengottuvelu, S., Periyasamy, T., Sethumathi, P. P., & Vadivukkarasi, S. (2021) · Archives of Physiology and Biochemistry · doi:10.1080/13813455.2021.1874017 · Cited by 48
Suissa, K., Schneeweiss, S., Kim, D. W., & Patorno, E. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14367 · Cited by 41
Serotonergic regulation of energy metabolism in peripheral tissues
Choi, W., Moon, J. H., & Kim, H. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0546 · Cited by 43
Lau, E. S., Braunwald, E., Morrow, D. A., Giugliano, R. P., Antman, E. M., Gibson, C. M., Scirica, B. M., Bohula, E. A., Wiviott, S. D., Bhatt, D. L., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.052339 · Cited by 43
Self-citationSerotonin signaling to regulate energy metabolism: a gut microbiota perspective
Li, G., Dong, S., Liu, C., Yang, J., Rensen, P. C. N., & Wang, Y. (2024) · Life Metabolism · doi:10.1093/lifemeta/loae039 · Cited by 45
“Lorcaserin, a high-selective 5-HTR 2C agonist that inhibits Serotonin signaling regulates energy metabolism 11/17 appetite [233], could alleviate obesity and diabetes in humans [209] with cardiovascular safety [97].”
Proteomic alterations underlie an association with teratozoospermia in obese mice sperm
Peng, Y., Zhao, W., Qu, F., Jing, J., Hu, Y., Liu, Y., & Ding, Z. (2019) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-019-0530-7 · Cited by 37
Benefit-Risk Assessment of Obesity Drugs: Focus on Glucagon-like Peptide-1 Receptor Agonists
Sandsdal, R. M., Juhl, C. R., & Torekov, S. S. (2019) · Drug Safety · doi:10.1007/s40264-019-00812-7 · Cited by 40
The year in cardiology 2018: prevention
Reiner, Ž., Laufs, U., Cosentino, F., & Landmesser, U. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy894 · Cited by 50
Cardiometabolic Medicine: Development of a New Subspecialty
Saxon, D. R., Reiter–Brennan, C., Blaha, M. J., & Eckel, R. H. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa261 · Cited by 38
Katsoulis, M., Stavola, B. L. D., Diaz‐Ordaz, K., Gomes, M., Lai, A. G., Λάγιου, Π., Wannamethee, S. G., Tsilidis, K. K., Lumbers, R. T., Denaxas, S., et al. (2021) · Epidemiology · doi:10.1097/ede.0000000000001393 · Cited by 41
“(2) The BigData@Heart Consortium, funded by the Innovative Medicines Initiative-2 Joint Undertaking under grant agreement No.”
MethodLorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial
Scirica, B. M., Bohula, E. A., Dwyer, J. P., Qamar, A., Inzucchi, S. E., McGuire, D. K., KEECH, A. C., Smith, S. R., Murphy, S. A., Im, K., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038341 · Cited by 38
Self-citationThe Renal Pathology of Obesity: Structure-Function Correlations
Tsuboi, N., & Okabayashi, Y. (2021) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2021.06.002 · Cited by 40
Bialer, M., Johannessen, S. I., Koepp, M. J., Levy, R. H., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2022) · Epilepsia · doi:10.1111/epi.17376 · Cited by 39
Self-citationAssociation between Serum Klotho Concentration and Heart Failure in Adults, NHANES 2007-2016
Cai, J., Zhang, L., Chen, C., Ge, J., Li, M., Zhang, Y., Liu, H., & Song, B. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.11.010 · Cited by 36
Hu, C. (2025) · Ageing Research Reviews · doi:10.1016/j.arr.2025.102727 · Cited by 38
RetractedSudlow, A. C., le Roux, C. W., & Pournaras, D. J. (2019) · Obesity Surgery · doi:10.1007/s11695-019-04206-7 · Cited by 34
Vasdeki, D., Koufakis, T., Tsamos, G., Busetto, L., Zebekakis, P. E., & Kotsa, K. (2022) · Nutrients · doi:10.3390/nu14224801 · Cited by 33
Conde, K., Fang, S., & Xu, Y. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01091-7 · Cited by 35
Rubio-Almanza, M., Cámara-Gómez, R., Hervás, D., Ponce-Marco, J. L., & Merino-Torres, J. F. (2018) · BMC Endocrine Disorders · doi:10.1186/s12902-018-0317-4 · Cited by 32
Porat, D., Marković, M., Zur, M., Fine‐Shamir, N., Azran, C., Shaked, G., Czeiger, D., Vaynshtein, J., Replyansky, I., Sebbag, G., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111949 · Cited by 31
Current Long-Term Pharmacotherapies for the Management of Obesity
Kim, B.-Y., Kang, S. M., Kang, J., Kim, K. K., Kim, B., Kim, S. J., Kim, Y., Kim, J. H., Kim, J. H., Nam, G. E., et al. (2020) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes20010 · Cited by 29
Cardiovascular Risks and Benefits of Medications Used for Weight Loss
Bramante, C. T., Raatz, S. J., Bomberg, E. M., Bensignor, M. O., & Ryder, J. R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00883 · Cited by 27
“During 3 years of followup, lorcaserin was associated with slightly lower hazard ratio of cardiovascular outcomes, and a non-significant improvement in non-fatal MI and stroke, and non-significant increase in cardiovascular death (events infrequent in both groups) (62).”
BackgroundBarriers and Solutions for Prescribing Obesity Pharmacotherapy
Fujioka, K., & Harris, S. R. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.02.007 · Cited by 28
Lorcaserin for Dravet Syndrome: A Potential Advance Over Fenfluramine?
Bialer, M., & Perucca, E. (2022) · CNS Drugs · doi:10.1007/s40263-022-00896-3 · Cited by 27
“Based on results of a large follow-up safety study [13], lorcaserin appeared to be largely devoid of cardiovascular toxicity.”
BackgroundMethodInfluentialKochhar, G. S., Desai, A., Syed, A., Grover, A., El‐Hachem, S., Abdul-Baki, H. A., Chintamaneni, P., Aoun, E. G., Kanna, S., Sandhu, D. S., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15721 · Cited by 29
Thomas, D. D., Waring, M. E., Ameli, O., Reisman, J. I., & Vimalananda, V. G. (2019) · Obesity · doi:10.1002/oby.22503 · Cited by 25
“The newer WMM, including lorcaserin, liraglutide, and phentermine/topiramate, have demonstrated a positive risk/benefit ratio in phase 3 and phase 4 clinical trials (29-33).”
BackgroundObesity management in the Saudi population
Aldubikhi, A. I. S. (2023) · Saudi Medical Journal · doi:10.15537/smj.2023.44.8.20220724 · Cited by 31
5-HT2C Receptor Stimulation in Obesity Treatment: Orthosteric Agonists vs. Allosteric Modulators
Przegaliński, E., Witek, K., Wydra, K., Kotlinska, J. H., & Filip, M. (2023) · Nutrients · doi:10.3390/nu15061449 · Cited by 25
“In contrast, the unwanted effects of fenfluramines and sibutramine, in randomized, double-blind, placebocontrolled, multinational clinical trials of lorcaserin treatment, were not associated with any increase in cardiovascular events among patients with high cardiovascular risk [88].”
BackgroundSingh, A. K., & Singh, R. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1703109 · Cited by 27
The risk of cardiovascular complications with current obesity drugs
Chao, A. M., Wadden, T. A., Berkowitz, R. I., Quigley, K., & Silvestry, F. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1806234 · Cited by 23
A primer on obesity-related cardiomyopathy
Samson, W. K., Yosten, G. L. C., & Remme, C. A. (2021) · Physiological Reviews · doi:10.1152/physrev.00023.2021 · Cited by 25
Recent advances in the treatment of patients with obesity and chronic kidney disease
Wahab, R. A., COHEN, R. V., & le Roux, C. W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2203517 · Cited by 25
Uddandrao, V. V. S., Chandrasekaran, P., Saravanan, G., Parim, B., Sengottuvelu, S., Ponmurugan, P., Vadivukkarasi, S., & Kumar, U. (2023) · Journal of Traditional and Complementary Medicine · doi:10.1016/j.jtcme.2023.08.004 · Cited by 22
The Fight Against Obesity Escalates: New Drugs on the Horizon and Metabolic Implications
Tsilingiris, D., Liatis, S., Dalamaga, Μ., & Kokkinos, A. D. (2020) · Current Obesity Reports · doi:10.1007/s13679-020-00378-x · Cited by 23
Vromen, T., Brouwers, R. W. M., Jorstad, H. T., Kraaijenhagen, R. A., Spee, R. F., Wittekoek, M. E., Cramer, M. J., van Hal, J. M. C., Hofstra, L., Kuijpers, P. M. J. C., et al. (2021) · Netherlands Heart Journal · doi:10.1007/s12471-021-01585-4 · Cited by 21
Pan, J., Yin, J., Gan, L., & Xue, J. (2022) · Obesity Reviews · doi:10.1111/obr.13521 · Cited by 23
Pharmacological Treatments and Natural Biocompounds in Weight Management
Gasmi, A., Mujawdiya, P. K., Nehaoua, A., Shanaida, M., Semenova, Y. M., Piscopo, S., Menzel, A., Voloshyn, V., Voloshyn, O., Shanaida, V., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16020212 · Cited by 24
“The study concluded that lorcaserin is a safe intervention for sustained weight loss without any adverse cardiovascular events in high-risk obese or overweight patients [61].”
BackgroundKato, E. T., & Kimura, T. (2020) · International Journal of Heart Failure · doi:10.36628/ijhf.2019.0013 · Cited by 22
Alsuhibani, A., Alrasheed, M., Gari, M., Hincapie, A. L., & Guo, J. J. (2022) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-021-01330-2 · Cited by 19
The role of anti-obesity medication in prevention of diabetes and its complications
Oh, T. J. (2019) · Journal of Obesity & Metabolic Syndrome · doi:10.7570/jomes.2019.28.3.158 · Cited by 19
Gorelik, E., Gorelik, B., Masarwa, R., Perlman, A., Raccah, B. H., & Matok, I. (2020) · International Journal of Obesity · doi:10.1038/s41366-020-0544-4 · Cited by 21
“and only for a subset of 27% of all study participants [25].”
BackgroundResult
Metadata
- Authors
- Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., Garcia-Castillo, A., Gupta, M., Leiter, L. A., Weissman, N. J., White, H. D., Patel, T., Francis, B., Miao, W., Perdomo, C., Dhadda, S., Bonaca, M. P., Ruff, C. T., Keech, A. C., Smith, S. R., Sabatine, M. S., & Scirica, B. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, Boston (E.A.B., S.D.W., J.K., K.I., A.Q., M.P.B., C.T.R., M.S.S., B.M.S.); the Cardiovascular Division, University of Texas Southwestern Medical Center, Dallas (D.K.M.); the Section of Endocrinology, Yale School of Medicine, New Haven, CT (S.E.I.); the Department of Medicine, University of Minnesota, Minneapolis (C.L.F.); the Partners Clinical Research Centre, Nassau,...
- ORCID
- Bohula, Erin A.
- Wiviott, Stephen D.
- McGuire, Darren K.
- Inzucchi, Silvio E.
- Kuder, Julia
- Fanola, Christina L.
- Qamar, Arman
- Budaj, Andrzej
- Gupta, Milan
- Leiter, Lawrence A.
- White, Harvey D.
- Patel, Tushar
- Perdomo, Carlos
- Dhadda, Shobha
- Bonaca, Marc P.
- Ruff, Christian T.
- Keech, Anthony C.
- Smith, Steven R.
- Sabatine, Marc S.
- Scirica, Benjamin M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-09-20
- Volume
- 379
- Issue
- 12
- Pages
- 1107-1117
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2888628330
- Cited by
- 265
- References
- 28
- Citations by year
- 2026: 12 · 2025: 18 · 2024: 20 · 2023: 32 · 2022: 30 · 2021: 36 · 2020: 41 · 2019: 57 · 2018: 18
- FWCI
- 24.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eisai
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- lorcaserin, cardiovascular safety, obesity, overweight, weight loss, appetite suppressants, major adverse cardiovascular events, non-inferiority, heart failure, hypoglycemia, atherosclerotic cardiovascular disease, weight management, adverse events, serious adverse events, cardiovascular risk factors, coronary revascularization, myocardial infarction
- MeSH terms
- Aged, Aortic Valve Insufficiency, Benzazepines, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Pulmonary, Hypoglycemia, Male, Middle Aged, Obesity, Risk Factors, Weight Loss, Anti-Obesity Agents, Overweight
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.